IFN-γ, TNF-α, IL-10, IL-17 and IL-22 secretion capacities and activation profile of T cells in psoriatic arthritis patients under disease-modifying antirheumatic drug therapy
- 1Department of Medical and Surgical Research, Hacettepe University Institute of Health Sciences
- 2Department of Internal Medicine, Division of Rheumatology, Hacettepe University Medical Faculty
- 3Department of Basic Oncology, Hacettepe University Cancer Institute
Abstract
Introduction: While biologic disease-modifying antirheumatic drugs (bDMARDs) have transformed management, achieving complete remission remains a challenge due to complex immune networks in Psoriatic arthritis (PsA). This study aimed to characterize the functional modulation of circulating T-helper (Th) and cytotoxic T (Tc) cells in PsA patients following conventional synthetic (csDMARD) and biologic therapy.
Methods: Peripheral blood mononuclear cells were collected from bDMARD-naïve PsA patients at baseline and six months after initiating csDMARD (primarily methotrexate, n=8) or bDMARD (primarily certolizumab, n=11) therapy. Using an optimized flow cytometry-based assay, we evaluated the secretion capacities of TNF-α, IFN-γ, IL-17, IL-22, and IL-10, alongside activation markers (CD40L, ICOS, CD38) in CD4 ⁺ Th and CD8 ⁺ Tc cells. Results were associated with clinical disease activity indices (DAPSA, BASDAI, PsAID-12, LEI).
Results: Both therapies significantly improved clinical scores yet failed to achieve immunological quiescence. A central finding was a significant increase in the percentage of TNF-secreting Th and Tc cells post-therapy, which may reflect a compensatory change in T-cell cytokine secretion following treatment. In the bDMARD cohort, Tc cells exhibited a significant expansion of subsets secreting IFN-γ, IL-17, and IL-10, suggesting a possible shift toward Type 1/Type 17-related cytokine responses. Baseline IL-17 and IL-10 levels correlated positively with high disease activity (BASDAI/PsAID-12), while post-treatment IL-17 and IL-22 secretory potential was specifically associated with persistent enthesitis (LEI scores).
Discussion: Despite clinical efficacy, DMARD therapy was associated with persistent alterations in T-cell cytokine profiles, including IFN-γ- and IL-17-producing T-cell populations, particularly within the CD8+ compartment. These findings suggest that peripheral immune profiling may provide additional insights into the immunological effects of therapy and could contribute to future personalized approaches for monitoring immune responses in patients with PsA.
Related
- Icotrokinra, a Targeted Oral Peptide, in Participants With Moderate-to-Severe Plaque Psoriasis and Self-Reported Psoriatic Arthritis: Results From a Pooled Analysis of the Phase 3 ICONIC-LEAD, ICONIC-ADVANCE 1, and ICONIC-ADVANCE 2 Trials.
- Extracapsular and joint-dominant hand and wrist MRI patterns in psoriatic and rheumatoid arthritis: an exploratory case-control study
- Exercise, physical activity, and physical fitness in psoriasis and psoriatic arthritis: an umbrella review
- Dynamics and activation of the Legionella Type IV secretion system
- Investigating the Role of Different Co-receptors on T-cell Activation Through IFN-γ Secretion Using Spatially Controlled Cell Monitoring Platform
BibTeX
@article{goksen2026ifnγ,
title = {{IFN-γ, TNF-α, IL-10, IL-17 and IL-22 secretion capacities and activation profile of T cells in psoriatic arthritis patients under disease-modifying antirheumatic drug therapy}},
author = {Sibel Goksen and Gizem Ayan and Umut Kalyoncu and Gunes Esendagli},
journal = {Frontiers in Immunology},
year = {2026},
month = oct,
doi = {10.3389/fimmu.2026.1863954},
url = {https://www.frontiersin.org/articles/10.3389/fimmu.2026.1863954/full},
note = {CC BY 4.0},
}
RIS
TY - JOUR
TI - IFN-γ, TNF-α, IL-10, IL-17 and IL-22 secretion capacities and activation profile of T cells in psoriatic arthritis patients under disease-modifying antirheumatic drug therapy
AU - Sibel Goksen
AU - Gizem Ayan
AU - Umut Kalyoncu
AU - Gunes Esendagli
PY - 2026
DA - 2026/10/09
JO - Frontiers in Immunology
DO - 10.3389/fimmu.2026.1863954
UR - https://www.frontiersin.org/articles/10.3389/fimmu.2026.1863954/full
AB - Introduction: While biologic disease-modifying antirheumatic drugs (bDMARDs) have transformed management, achieving complete remission remains a challenge due to complex immune networks in Psoriatic arthritis (PsA). This study aimed to characterize the functional modulation of circulating T-helper (Th) and cytotoxic T (Tc) cells in PsA patients following conventional synthetic (csDMARD) and biologic therapy. Methods: Peripheral blood mononuclear cells were collected from bDMARD-naïve PsA patients at baseline and six months after initiating csDMARD (primarily methotrexate, n=8) or bDMARD (primarily certolizumab, n=11) therapy. Using an optimized flow cytometry-based assay, we evaluated the secretion capacities of TNF-α, IFN-γ, IL-17, IL-22, and IL-10, alongside activation markers (CD40L, ICOS, CD38) in CD4 ⁺ Th and CD8 ⁺ Tc cells. Results were associated with clinical disease activity indices (DAPSA, BASDAI, PsAID-12, LEI). Results: Both therapies significantly improved clinical scores yet failed to achieve immunological quiescence. A central finding was a significant increase in the percentage of TNF-secreting Th and Tc cells post-therapy, which may reflect a compensatory change in T-cell cytokine secretion following treatment. In the bDMARD cohort, Tc cells exhibited a significant expansion of subsets secreting IFN-γ, IL-17, and IL-10, suggesting a possible shift toward Type 1/Type 17-related cytokine responses. Baseline IL-17 and IL-10 levels correlated positively with high disease activity (BASDAI/PsAID-12), while post-treatment IL-17 and IL-22 secretory potential was specifically associated with persistent enthesitis (LEI scores). Discussion: Despite clinical efficacy, DMARD therapy was associated with persistent alterations in T-cell cytokine profiles, including IFN-γ- and IL-17-producing T-cell populations, particularly within the CD8+ compartment. These findings suggest that peripheral immune profiling may provide additional insights into the immunological effects of therapy and could contribute to future personalized approaches for monitoring immune responses in patients with PsA.
SN - 1664-3224
ER -